382 results on '"Buxhofer-Ausch, Veronika"'
Search Results
2. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
3. TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer
4. Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion
5. BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial
6. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
7. Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
8. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
9. Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange
10. Alternate‐day dosing of caplacizumab for immune‐mediated thrombotic thrombocytopenic purpura
11. SFRP1 promotor methylation analysis of FTA card touch-prep samples derived from colonic polyps
12. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
13. Austrian recommendations for the management of essential thrombocythemia
14. Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options—A Single-Center Experience
15. A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting: R-EFECT study
16. Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients—A Retrospective Single-Center Analysis
17. PB2134: BCMA-TARGETED THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – A SINGLE CENTER EXPERIENCE
18. PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
19. Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients
20. Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
21. Austrian recommendations for the management of polycythemia vera
22. Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation
23. Abundance of the Organic Anion-transporting Polypeptide OATP4A1 in Early-Stage Colorectal Cancer Patients: Association With Disease Relapse
24. BendaEAM Versus BEAM as Conditioning Regimen for ASCT in Patients with Relapsed Lymphoma (BEB): A Multicentre, Randomised, Phase II Trial
25. Management of Immune Thrombotic Thrombocytopenic Purpura Without Therapeutic Plasma Exchange
26. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
27. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
28. Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy
29. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
30. A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients
31. Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network
32. Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
33. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
34. Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation.
35. Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
36. Iron metabolism and iron supplementation in cancer patients
37. Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms
38. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura
39. Impact of white blood cell counts at diagnosis and during follow‐up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis
40. Intensive consolidation with G‐CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years
41. Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
42. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
43. A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
44. Correction to: Ruxolitinib therapy formyelofibrosis in Austria: Consensus on therapy management
45. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
46. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
47. Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura
48. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
49. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
50. Sensitive Detection of KRAS Mutations in Archived Formalin-Fixed Paraffin-Embedded Tissue Using Mutant-Enriched PCR and Reverse-Hybridization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.